147 related articles for article (PubMed ID: 37256213)
1. Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA
Feuerstadt P; Harvey A; Yoho DS; Garcia-Diaz JB; Knapple WL; Bancke L
Open Forum Infect Dis; 2023 May; 10(5):ofad171. PubMed ID: 37256213
[TBL] [Abstract][Full Text] [Related]
2. Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA
Knapple WL; Yoho DS; Sheh A; Thul J; Feuerstadt P
Therap Adv Gastroenterol; 2024; 17():17562848241239547. PubMed ID: 38529070
[TBL] [Abstract][Full Text] [Related]
3. Safety of fecal microbiota, live-jslm (REBYOTA
Lee C; Louie T; Bancke L; Guthmueller B; Harvey A; Feuerstadt P; Khanna S; Orenstein R; Dubberke ER
Therap Adv Gastroenterol; 2023; 16():17562848231174277. PubMed ID: 37333464
[TBL] [Abstract][Full Text] [Related]
4. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
5. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
J Clin Gastroenterol; 2023 Nov; ():. PubMed ID: 38019088
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent
Garey KW; Dubberke ER; Guo A; Harvey A; Yang M; García-Horton V; Fillbrunn M; Wang H; Tillotson GS; Bancke LL; Feuerstadt P
Open Forum Infect Dis; 2023 Aug; 10(8):ofad383. PubMed ID: 37564743
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
Feuerstadt P; Allegretti JR; Dubberke ER; Guo A; Harvey A; Yang M; Garcia-Horton V; Fillbrunn M; Tillotson G; Bancke LL; LaPlante K; Garey KW; Khanna S
Infect Dis Ther; 2024 Jan; 13(1):221-236. PubMed ID: 38236515
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
9. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
[TBL] [Abstract][Full Text] [Related]
10. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
11. Live Biotherapeutic Products for the Prevention of Recurrent
Pettit NN; Shaeer KM; Chahine EB
Ann Pharmacother; 2024 Mar; ():10600280241239685. PubMed ID: 38546138
[TBL] [Abstract][Full Text] [Related]
12. A review of fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection.
Hunt A; Drwiega E; Wang Y; Danziger L
Am J Health Syst Pharm; 2024 Mar; ():. PubMed ID: 38470061
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
14. Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent
Feuerstadt P; Oneto C; Tillotson G; Van Hise NW
Patient Prefer Adherence; 2023; 17():2153-2159. PubMed ID: 37667688
[TBL] [Abstract][Full Text] [Related]
15. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
Khanna S; Pardi DS; Jones C; Shannon WD; Gonzalez C; Blount K
Clin Infect Dis; 2021 Oct; 73(7):e1613-e1620. PubMed ID: 32966574
[TBL] [Abstract][Full Text] [Related]
16. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis.
Doosetty S; Umeh C; Eastwood W; Samreen I; Penchala A; Kaur H; Chilinga C; Kaur G; Mohta T; Nakka S; Tangirala P; Nakka S
Cureus; 2024 Apr; 16(4):e58862. PubMed ID: 38800285
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Vaughn BP; Fischer M; Kelly CR; Allegretti JR; Graiziger C; Thomas J; McClure E; Kabage AJ; Khoruts A
Clin Gastroenterol Hepatol; 2023 May; 21(5):1330-1337.e2. PubMed ID: 36126907
[TBL] [Abstract][Full Text] [Related]
19. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
20. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.
Gonzales-Luna AJ; Carlson TJ; Garey KW
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S487-S496. PubMed ID: 38051970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
